The Effects of Early Onset Tranquilizers, Sedatives, and Sleeping Pills Use on Recent Consumption Among Adolescents.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
Historique:
pubmed:
25
3
2021
medline:
19
3
2022
entrez:
24
3
2021
Statut:
ppublish
Résumé
Adolescents' consumption of tranquilizers, sedatives, and sleeping pills (TSSp) has increased during the last few decades, and TSSp are currently among the substances with the lowest age-of-onset. We characterized current-use patterns of TSSp consumers by age when first taken. This study used individualized secondary data retrieved from the 2016 Spanish State Survey on Drug Use in Secondary Education (16-18-year-olds), and included all subjects who reported having taken TSSp at any point, but excluded those who had started during the previous year (n = 1502). Logistic regression models were used to obtain adjusted odds ratios (aOR) for associations between early TSSp consumption (<14 years) and current TSSp use patterns, adjusted for sociodemographic factors. About 17.9% of respondents had taken TSSp (average age-of-onset = 13.7) and 45% of these without a prescription. TSSp consumption at <14 years was higher for males and nonrepeaters. Having begun to use TSSp < 14 years was associated with both higher probability of consumption in the last month (aOR = 1.41; 95%CI:1.12-1.77) and daily/almost daily consumption in the last month (aOR = 1.56; 95CI%:1.16-2.08). The results of this study show there is a high proportion of 16 to 18 TSSp student consumers - both prescribed and nonprescribed; it also establishes that early onset-of-use is associated with higher levels of intensive use later on.
Sections du résumé
BACKGROUND
Adolescents' consumption of tranquilizers, sedatives, and sleeping pills (TSSp) has increased during the last few decades, and TSSp are currently among the substances with the lowest age-of-onset. We characterized current-use patterns of TSSp consumers by age when first taken.
METHODS
This study used individualized secondary data retrieved from the 2016 Spanish State Survey on Drug Use in Secondary Education (16-18-year-olds), and included all subjects who reported having taken TSSp at any point, but excluded those who had started during the previous year (n = 1502). Logistic regression models were used to obtain adjusted odds ratios (aOR) for associations between early TSSp consumption (<14 years) and current TSSp use patterns, adjusted for sociodemographic factors.
RESULTS
About 17.9% of respondents had taken TSSp (average age-of-onset = 13.7) and 45% of these without a prescription. TSSp consumption at <14 years was higher for males and nonrepeaters. Having begun to use TSSp < 14 years was associated with both higher probability of consumption in the last month (aOR = 1.41; 95%CI:1.12-1.77) and daily/almost daily consumption in the last month (aOR = 1.56; 95CI%:1.16-2.08).
CONCLUSIONS
The results of this study show there is a high proportion of 16 to 18 TSSp student consumers - both prescribed and nonprescribed; it also establishes that early onset-of-use is associated with higher levels of intensive use later on.
Identifiants
pubmed: 33758113
doi: 10.1097/ADM.0000000000000839
pii: 01271255-202202000-00020
doi:
Substances chimiques
Hypnotics and Sedatives
0
Sleep Aids, Pharmaceutical
0
Tranquilizing Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23-e29Informations de copyright
Copyright © 2021 American Society of Addiction Medicine.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
UNODC. World Drug Report 2018. Global overview of drug demand and supply. Latest trends, corss-cutting issues. Vienna; 2018. Available at: https://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_2_GLOBAL.pdf . Accessed February 9, 2021.
Sidorchuk A, Isomura K, Molero Y, et al. Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study. PLoS Med 2018; 15 (8):e1002635.
Lagerberg T, Molero Y, D’Onofrio BM, et al. Antidepressant prescription patterns and CNS polypharmacy with antidepressants among children, adolescents, and young adults: a population-based study in Sweden. Eur Child Adolesc Psychiatry 2019; 28 (8):1137–1145.
Franke C, Fegert JM, Kruger U, Kolch M. Prescriptions of psychotropic drugs to children and adolescents in Germany. Z Kinder Jugendpsychiatr Psychother 2016; 44 (4):259–274.
Tsai CY, Yang HC, Islam M, et al. Psychotropic medications prescribing trends in adolescents: A nationwide population-based study in Taiwan. Int J Qual Health Care 2017; 29 (6):861–866.
Schepis TS, West BT, Teter CJ, McCabe SE. Prevalence and correlates of co-ingestion of prescription tranquilizers and other psychoactive substances by U.S. high school seniors: Results from a national survey. Addict Behav 2016; 52:8–12.
Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2009; (3):CD005170.
Dell’osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 2013; 28 (1):7–20.
Lader M. Benzodiazepines revisited--will we ever learn? Addiction 2011; 106 (12):2086–2109.
EMCDDA. European Drug Report 2018: Trends and Developments. 2018; Luxembourg: Publications Office of the European Union, Available at: http://www.emcdda.europa.eu/system/files/publications/8585/20181816_TDAT18001ENN_PDF.pdf . Accessed February 9, 2021.
Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2017 National Survey on Drug Use and Health. 2018; Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Available at: https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHFFR2017/NSDUHFFR2017.pdf . Accessed February 9, 2021.
Observatorio Español de las Drogas y las Adicciones. Informe 2018. Alcohol, tabaco y drogas ilegales en España. Encuesta sobre uso de drogas en enseñanzas secundarias en España (ESTUDES), 1994–2016. 2018; Madrid, Spain: Ministerio de Sanidad, Consumo y Bienestar Social, Delegación para el Plan Nacional sobre Drogas, Available at: http://www.pnsd.mscbs.gob.es/profesionales/sistemasInformacion/sistemaInformacion/pdf/ESTUDES_2018_Informe.pdf . Accessed February 9, 2021.
Carrasco-Garrido P, Jimenez-Trujillo I, Hernandez-Barrera V, Garcia-Gomez-Heras S, Alonso-Fernandez N, Palacios-Cena D. Trends in the misuse of tranquilizers, sedatives, and sleeping pills by adolescents in Spain, 2004–2014. J Adolesc Health 2018; 63 (6):709–716.
McCabe SE, West BT, Morales M, Cranford JA, Boyd CJ. Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study. Addiction 2007; 102 (12):1920–1930.
Pilatti A, Read JP, Pautassi RM. ELSA 2016 cohort: alcohol, tobacco, and marijuana use and their association with age of drug use onset, risk perception, and social norms in Argentinean College Freshmen. Front Psychol 2017; 8:1452.
Stinson FS, Grant BF, Dawson DA, Ruan WJ, Huang B, Saha T. Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2005; 80 (1):105–116.
Boyd CJ, West B, McCabe SE. Does misuse lead to a disorder? The misuse of prescription tranquilizer and sedative medications and subsequent substance use disorders in a U.S. longitudinal sample. Addict Behav 2018; 79:17–23.
Blanco C, Secades-Villa R, Garcia-Rodriguez O, Labrador-Mendez M, Wang S, Schwartz RP. Probability and predictors of remission from life-time prescription drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Psychiatr Res 2013; 47 (1):42–49.
Taibi DM, Landis CA, Petry H, Vitiello MV. A systematic review of valerian as a sleep aid: Safe but not effective. Sleep Med Rev 2007; 11 (3):209–230.
Vicente Sanchez MP, Macias Saint-Gerons D, de la Fuente Honrubia C, Gonzalez Bermejo D, Montero Corominas D, Catala-Lopez F. Trends of use of anxiolytics and hypnotics in Spain from 2000 to 2011. Rev Esp Salud Publica 2013; 87 (3):247–255.
Sanchez-Niubo A, Sordo L, Barrio G, Indave B, Domingo-Salvany A. Onset and progression of drug use in the general population of Catalonia, Spain. Adicciones 2020; 32 (1):32–40.
O'Sullivan K, Reulbach U, Boland F, et al. Benzodiazepine prescribing in children under 15 years of age receiving free medical care on the General Medical Services scheme in Ireland. BMJ Open 2015; 5 (6):e007070.
Reinblatt SP, Walkup JT. Psychopharmacologic treatment of pediatric anxiety disorders. Child Adolesc Psychiatr Clin N Am 2005; 14 (4):877–908. x.
Novak SP, Hakansson A, Martinez-Raga J, Reimer J, Krotki K, Varughese S. Nonmedical use of prescription drugs in the European Union. BMC Psychiatry 2016; 16:274.
Kokkevi A, Fotiou A, Arapaki A, Richardson C. Prevalence, patterns, and correlates of tranquilizer and sedative use among European adolescents. J Adolesc Health 2008; 43 (6):584–592.
Opaleye ES, Noto AR, Sanchez ZM, et al. Nonprescribed use of tranquilizers or sedatives by adolescents: a Brazilian national survey. BMC Public Health 2013; 13:499.
Palamar JJ, Le A, Mateu-Gelabert P. Not just heroin: Extensive polysubstance use among US high school seniors who currently use heroin. Drug Alcohol Depend 2018; 188:377–384.
Palamar JJ, Han BH, Martins SS. Shifting characteristics of nonmedical prescription tranquilizer users in the United States, 2005–2014. Drug Alcohol Depend 2019; 195:1–5.
Young AM, Glover N, Havens JR. Nonmedical use of prescription medications among adolescents in the United States: a systematic review. J Adolesc Health 2012; 51 (1):6–17.
Kokkevi A, Kanavou E, Richardson C, et al. Polydrug use by European adolescents in the context of other problem behaviours. Nordic Stud Alcohol Drugs 2014; 31 (4):323–342.
Owens JA, Rosen CL, Mindell JA. Medication use in the treatment of pediatric insomnia: results of a survey of community-based pediatricians. Pediatrics 2003; 111 (5 Pt 1):e628–e635.
Bourcier E, Korb-Savoldelli V, Hejblum G, Fernandez C, Hindlet P. A systematic review of regulatory and educational interventions to reduce the burden associated with the prescriptions of sedative-hypnotics in adults treated for sleep disorders. PLoS One 2018; 13 (1):e0191211.
Fisher J, Sanyal C, Frail D, Sketris I. The intended and unintended consequences of benzodiazepine monitoring programmes: a review of the literature. J Clin Pharm Ther 2012; 37 (1):7–21.